Download PDF
Thromb Haemost 1995; 74(01): 066-070
DOI: 10.1055/s-0038-1642654
Symposium
Natural Inhibitors of Fibrinolysis
Schattauer GmbH Stuttgart

The PAI-1/Vitronectin Interaction: Two Cats in a Bag?

Gang Deng
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
,
Gordon Royle
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
,
Dietmar Seiffert
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
,
David J Loskutoff
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 190: 381-387
    PubMedGoogle Scholar
  • 2 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol 9 W.B.Saunders; Philadelphia, PA: 1989: 87-115
    Google Scholar
  • 3 Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovascular Med 1991; 1: 99-102
    CrossrefPubMedGoogle Scholar
  • 4 Dano K, Andreasen P, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 5 Vassalh J-D, Sappino A-P, Berlin D. The plasminogen activator/plasmin system. J din Invest 1991; 88: 1067-1072
    PubMedGoogle Scholar
  • 6 Carrell R, Travis J. a1-Antitrypsin and the serpins: variation and countervariation. TIBS 1985; 20-24
    PubMedGoogle Scholar
  • 7 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen ativators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
    PubMedGoogle Scholar
  • 8 Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, Muller-Berghaus G, Collen D. Purfication and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-15461
    PubMedGoogle Scholar
  • 9 Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-128
    CrossrefPubMedGoogle Scholar
  • 10 Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 1989; 264: 936-939
    PubMedGoogle Scholar
  • 11 Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Muller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
    PubMedGoogle Scholar
  • 12 Seiffert D, Wagner NN, Loskutoff DJ. Seru-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990; 111: 1283-1291
    CrossrefPubMedGoogle Scholar
  • 13 Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991; 266: 2824-2830
    CrossrefPubMedGoogle Scholar
  • 14 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-728
    PubMedGoogle Scholar
  • 15 Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT. Mapping of binding sites forheparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin’s heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin foimation. J Biol Chem 1992; 267: 12098-12105
    PubMedGoogle Scholar
  • 16 Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, Sakata Y. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistiy 1993; 32: 2314-2320
    PubMedGoogle Scholar
  • 17 Tomasini BR, Mosher DF. Vitronectin. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol (10) W.B.Saunders; Philadelphia, PA: 1990. 10. 269-305
    Google Scholar
  • 18 Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994; 1208: 104-110
    CrossrefPubMedGoogle Scholar
  • 19 Lawrence DA, Beikenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-15228
    PubMedGoogle Scholar
  • 20 Ciambrone G, Loskutoff DJ. unpublished observations
    PubMed
  • 21 van Meijer M, Gebbink RK, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Lett 1994; 352: 342-346
    CrossrefPubMedGoogle Scholar
  • 22 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273
    CrossrefPubMedGoogle Scholar
  • 23 Ehrlich HJ, Gebbink RK, Keijer J, Pannekoek H. Elucidation of structural requirements of plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11606-11611
    PubMedGoogle Scholar
  • 24 Nakashima N, Miyazaki K, Ishikawa M, Yatohgo T, Ogawa H, Uchibori H, Matsumoto I, Seno N, Hayashi M. Vitronectin diversity in evolution but uniformity in ligand binding and size of the core polypeptide. Biochim Biophys Acta 1992; 1120: 1-10
    CrossrefPubMedGoogle Scholar
  • 25 Fiyklund L, Uthne K, Sievertsson H. Isolation and characterization of polypeptides from human plasma enhancing the growth of human normal cells in culture. Biochem Biophys Res Comm 1974; 61: 950-956
    CrossrefPubMedGoogle Scholar
  • 26 Heldin C-H, Fryklund L. Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. Science 1981; 213: 1121-1123
    PubMedGoogle Scholar
  • 27 Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-2524
    PubMedGoogle Scholar
  • 28 Salonen E-M, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343
    PubMedGoogle Scholar
  • 29 Sigurdardottir O, Wiman B. Studies on the interaction between plasminogen inhibitor-1 and vitronectin. Fibrinolysis 1992; 6: 27-32
    PubMedGoogle Scholar
  • 30 Seiffert D, Loskutoff DJ. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terimal fragment of bovine vitronectin. Biochim Biophys Acta 1991; 1078: 23-30
    CrossrefPubMedGoogle Scholar
  • 31 Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. J Biol Chem 1994 269: 2659-2666
    PubMedGoogle Scholar
  • 32 Tomassini-Johansson BR, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993; 13: 203-214
    CrossrefPubMedGoogle Scholar
  • 33 Gechtman Z, Shaima R, Kreizman T, Fridkin M, Shaltiel S. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. FEBS Lett 1993; 315: 293-297
    CrossrefPubMedGoogle Scholar
  • 34 Wagner O, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 1989; 84: 647-655
    CrossrefPubMedGoogle Scholar
  • 35 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastractural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
    PubMedGoogle Scholar
  • 36 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissociation. J Biol Chem 1992; 267: 17128-17135
    PubMedGoogle Scholar
  • 37 Lambers JW J, Cammenga M, Konig B, Pannekoek H, van Mourik JA. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-17496
    PubMedGoogle Scholar
  • 38 Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations cm its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 39 Decleik PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 40 Woolf N. Thrombosis and atherosclerosis. In: Heamostasis and Thrombosis. Bloom AL, Thomas DP. eds Churchill Livingstone; Edinburgh: 1981: 527-553
    Google Scholar
  • 41 Levi M, Biemond BJ, Van Zooneveld AJ, Woulter ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305
    CrossrefPubMedGoogle Scholar
  • 42 Potter van Loon BJ, Rijken DC, Broomer EJ P, Van der Maas AP C. The amount of plasminogen, tissue type plasminogen activatorand plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992; 67: 101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Merberg DM, Fitz U, Temple P, Giannotti J, Murtha P, Fitzgerald M, Scaltreto J, Kelleher K, Preissner K, Kriz R, Jacobs K, Turner K. A comparison of vitronectin and megakaryocyte stimulating factor. In: Biology of Vitronectins and their Receptors. Rosenblatt S, Preissner KR, Kost C, Wegerhoff J, Mosher DF. eds. Elsevier Science Publishers B.V.; The Netherlands: 1993: 45-55
    Google Scholar
  • 44 Grundmann U, Romisch J, Siebold B, Bohn H, Amann E. Cloning and expression of a cDNA encoding human placental protein 11, a putative serine protease with diagnostic significance as a tumor marker. DNA Cell Biol 1990; 9: 243-250
    CrossrefPubMedGoogle Scholar
  • 45 Baughman G, Lesley J, Trotter J, Hyman R, Bourgeois S. Tcl-30, a new T cell-specific gene expressed in immature glucocorticoid-sensitive thymocytes. J Immunol 1992; 149: 1488-1496
    PubMedGoogle Scholar
  • 46 Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem 1990; 265: 17506-17511
    PubMedGoogle Scholar
  • 47 Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991; 88: 9402-9406
    CrossrefPubMedGoogle Scholar